Formic Acid

Formic Acid

SCHEMBL6717624

Cc1ccccc1NC(=O)[C@H](N)C(C)C.O=CO

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
PGR P06401 1/20 0.50
SCN1A P35498 1/20 0.50
SCN2A Q99250 1/20 0.50
SCN3A Q9NY46 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
HPGD P15428 3/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
ITGB3 P05106 2/20 0.48
ITGAV P06756 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL6723524 1.00 POLB (0.50) POLBPGRSCN1ASCN2ASCN3A
Formic Acid SCHEMBL6723307 1.00 POLB (0.50) POLBPGRSCN1ASCN2ASCN3A
SCHEMBL8347817 0.94 NPC1 (0.56) POLBPGRSCN1ASCN2ASCN3A
SCHEMBL6715814 0.94 NPC1 (0.56) POLBPGRSCN1ASCN2ASCN3A
SCHEMBL6717651 0.94 NPC1 (0.56) POLBPGRSCN1ASCN2ASCN3A
Formic Acid SCHEMBL6715539 0.88 NPC1 (0.53) POLBPGRSCN1ASCN2ASCN3A
Formic Acid SCHEMBL6719239 0.84 POLB (0.49) POLBPGRSCN1ASCN2ASCN3A
Formic Acid SCHEMBL6717292 0.81 CYP1A2 (0.53) POLBPGRSCN1ASCN2ASCN3A
Formic Acid SCHEMBL6715482 0.81 CYP1A2 (0.53) POLBPGRSCN1ASCN2ASCN3A
SCHEMBL8346804 0.80 NPC1 (0.60) POLBPGRSCN1ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 POLB 4182/4885PGR 2543/4885SCN1A 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.